增强器重编程是SMARCA2降解剂在SMARCA4突变癌症中的治疗效益的基础
Sasikumar Kotagiri1, Nicholas Blazanin1, Yuanxin Xi2
1Department of Cardiovascular and Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cell chemical biology
|October 8, 2024
概括
用新的PROTAC YD23准SMARCA2为SMARCA4突变肺癌提供了一种合成致命策略. SMARCA2 降解会破坏细胞增殖增强剂,并抑制瘤生长.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 非小细胞肺癌 (NSCLC) 经常存在SWI/SNF染色体重塑复杂子单元的突变,如SMARCA4和ARID1A.
- 在SMARCA4突变癌症中,SMARCA2具有合成致命性,这表明SMARCA2是潜在的治疗标.
- 开发选择性SMARCA2抑制剂一直是NSCLC治疗的一个重大挑战.
研究的目的:
- 开发一种使用蛋白质溶解向嵌合体 (PROTAC) 技术的强效和选择性SMARCA2降解剂.
- 阐明SMARCA2降解影响SMARCA4突变细胞中染色质可访问性和基因表达的分子机制.
- 在SMARCA4突变NSCLC的临床前模型中评估SMARCA2降解剂的治疗疗效.
主要方法:
- 结构-活动关系 (SAR) 研究被用于设计和优化PROTAC YD23.
- 在癌细胞中评估了SMARCA2降解,随后使用ATAC-seq. 分析了染色质可访问性的分析.
- 研究了YAP/TEAD在SMARCA2中介生长中的作用,并在SMARCA4突变异因移植中测试了YD23的疗效.
主要成果:
- 确定YD23是一种强效和选择性的PROTAC,有效降解SMARCA2.
- SMARCA2 降解导致增强器格局的重编程,减少了与增殖相关的基因的染色质可访问性.
- 确定YAP/TEAD途径对SMARCA4突变细胞生长至关重要,YD23在体内显示出显著的瘤生长抑制.
结论:
- 通过PROTAC YD23降解SMARCA2代表了SMARCA4突变NSCLC的一个有希望的合成致命治疗策略.
- YD23的机制涉及改变增强可访问性和影响YAP/TEAD驱动的扩散.
- 这些发现支持SMARCA2降解剂的临床开发,用于治疗特定的肺癌亚型.
相关概念视频
Somatic to iPS Cell Reprogramming
2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
Conservative Site-specific Recombination and Phase Variation
5.9K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
5.9K
Induced Pluripotent Stem Cells
3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
3.9K
Methods of Nuclear Reprogramming
1.8K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
1.8K


